Gastrointestinal tract morphological alteration by unpleasant physical treatment and modulating role of<i>Lactobacillus</i>in broilers

Meimandipour, Amir; Hair-Bejo, M.; Mustafa, Shuhaimi; Azhar, K.; Soleimani, A. F.; Rasti, Babak; Yazid, A.M.

doi:10.1080/00071660903394455

Cited by 33 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, higher SCFA excretion and increased PYY and PP expression in the NDAPS1 group than the NDS group might be due to an increase in the populations of Lactobacillus spp. 52 , 53 .…”

Section: Discussionmentioning

confidence: 99%

A combination of Lactobacillus mali APS1 and dieting improved the efficacy of obesity treatment via manipulating gut microbiome in mice

Chen

Yang

Lin

et al. 2018

Sci Rep

View full text Add to dashboard Cite

The difficulty of long-term management has produced a high rate of failure for obesity patients. Therefore, improving the efficacy of current obesity treatment is a significant goal. We hypothesized that combining a probiotic Lactobacillus mali APS1 intervention with dieting could improve the efficacy of obesity and hepatic steatosis treatment compared to dieting alone. Mice were fed a high-fat diet for 6 weeks and then treated with: saline + normal diet and APS1 + normal diet (NDAPS1) for 3 weeks. NDAPS1 accelerated body weight loss and reduced caloric intake and fat accumulation. The fecal microbiome showed that accelerating weight loss by NDAPS1 resulted in restoring intestinal microbiota toward a pre-obese state, with alteration of specific changes in the obesity-associated bacteria. APS1 manipulated the gut microbiome’s obesity-associated metabolites, followed by regulation of lipid metabolism, enhancement of energy expenditure and inhibition of appetite. The specific hepatic metabolites induced by the APS1-manipulated gut microbiome also contributed to the amelioration of hepatic steatosis. Our results highlighted a possible microbiome and metabolome that contributed to accelerating weight loss following treatment with a combination of APS1 and dieting and suggested that probiotics could serve as a potential therapy for modulating physiological function and downstream of the microbiota.

show abstract

“…Besides, higher SCFA excretion and increased PYY and PP expression in the NDAPS1 group than the NDS group might be due to an increase in the populations of Lactobacillus spp. 52 , 53 .…”

Section: Discussionmentioning

confidence: 99%

A combination of Lactobacillus mali APS1 and dieting improved the efficacy of obesity treatment via manipulating gut microbiome in mice

Chen

Yang

Lin

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The mechanism of stimulation of Faecalibacterium growth is unclear. In a simulated model of caecal fermentation, the supplementation of certain Lactobacillus strains resulted in similar enhancement (Meimandipour et al, 2010). It was hypothesised that lactate produced by Lactobacillus in the caecal content improved the growth of butyric producers such as Faecalibacterium prausnitzii.…”

Section: Discussionmentioning

confidence: 99%

454 pyrosequencing reveals changes in the faecal microbiota of adults consumingLactobacillus caseiZhang

Zhang

Wang

Guo

et al. 2014

FEMS Microbiol Ecol

View full text Add to dashboard Cite

Probiotics are believed to help to maintain a healthy balance of the human gut microbiota. Lactobacillus casei Zhang (LcZ) is a novel potential probiotic isolated from the naturally fermented food koumiss. To better understand the impact of this potential probiotic on human intestinal microbiota, 24 subjects were randomly recruited for a longitudinal study: the subjects were required to consume LcZ for 28 days, and faecal samples were collected prior to, during and after the LcZ consumption phase. Alterations in the gut microbiota were monitored using 454 pyrosequencing and quantitative polymerase chain reaction(q-PCR) technologies. We found that the consumption of LcZ significantly altered the composition of intestinal microbiota (P < 0.001) and the gut microbiota diversity. Further analysis at the genus level revealed a positive correlation between LcZ and Prevotella, Lactobacillus, Faecalibacterium, Propionibacterium, Bifidobacterium and an unidentified genus from Bacteroidaceae and Lachnospiraceae and a negative correlation between LcZ administration and the presence of Clostridium, Phascolarctobacterium, Serratia, Enterococcus, Shigella and Shewanella. Furthermore, these changes were confirmed by q-PCR data.

show abstract

“…Previous studies have shown that L. salivarius produces abundant propionate/butyrate (16,17). Additionally, in previous studies, improved barrier function by SCFA was reported (18)(19)(20). SCFAs such as butyrate and acetate are known to protect intestinal barrier integrity by regulating through the activation of AMPK and TLR4.…”

Section: Lactobacillus Salivarius Bp121 Prevents Cisplatin-induced Acmentioning

confidence: 91%

Lactobacillus salivarius BP121 prevents cisplatin‑induced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and p‑cresol sulfate via alleviating dysbiosis

Lee¹,

Park

Kim³

et al. 2020

Int J Mol Med

View full text Add to dashboard Cite

The gut microbiota is important for maintaining the integrity of the intestinal barrier, promoting immunological tolerance and carrying out metabolic activities that have not evolved in hosts. Intestinal dysbiosis is associated with chronic kidney disease and probiotic supplementation has been shown to be beneficial. However, it is not known whether gut microorganisms-specifically, lactic acid bacteria (LAB) can protect against acute kidney injury (AKI). To address this issue, the present study investigated the effects of Lactobacillus salivarius BP121, an intestinal LAB isolated from the feces of newborns, in a rat model of cisplatin-induced AKI and also in Caco-2 human intestinal epithelial cells. BP121 prevented cisplatin-induced AKI in rats, as demonstrated by decreases in inflammation and oxidative stress in kidney tissue and in serum levels of uremic toxins such as indoxyl sulfate (IS) and p-cresol sulfate (PCS). BP121 also reduced intestinal permeability, as determined using fluorescein isothiocyanate-dextran by immunohistochemical detection of tight junction (TJ) proteins such as zona occludens-1 and occludin. The abundance of Lactobacillus spp., which are beneficial intestinal flora, was increased by BP121; this was accompanied by an increase in the concentrations of short-chain fatty acids in feces. Additionally, H 2 O 2 -induced TJ protein damage was reduced in Caco-2 cells treated with BP121 culture supernatant, an effect that was reversed by the 5' AMP-activated protein kinase (AMPK) inhibitor Compound C and Toll-like receptor (TLR)4 inhibitor TLR4-IN-C34. In conclusion, this study demonstrated that L. salivarius BP121 protects against cisplatin-induced AKI by decreasing inflammation and oxidative stress and this renoprotective effect is partially mediated by modulating the gut environment and thereby suppressing IS and PCS production as well as by regulating AMPK and TLR4 dependent TJ assembly.

show abstract

Gastrointestinal tract morphological alteration by unpleasant physical treatment and modulating role ofLactobacillusin broilers

Cited by 33 publications

References 27 publications

A combination of Lactobacillus mali APS1 and dieting improved the efficacy of obesity treatment via manipulating gut microbiome in mice

A combination of Lactobacillus mali APS1 and dieting improved the efficacy of obesity treatment via manipulating gut microbiome in mice

454 pyrosequencing reveals changes in the faecal microbiota of adults consumingLactobacillus caseiZhang

Lactobacillus salivarius BP121 prevents cisplatin‑induced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and p‑cresol sulfate via alleviating dysbiosis

Contact Info

Product

Resources

About